These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 11745184

  • 1. A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
    Gradishar WJ, Stephenson P, Glover DJ, Neuberg DS, Moore MR, Windschitl HE, Piel I, Abeloff MD.
    Cancer; 2001 Nov 15; 92(10):2517-22. PubMed ID: 11745184
    [Abstract] [Full Text] [Related]

  • 2. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group.
    Planting AS, Catimel G, de Mulder PH, de Graeff A, Höppener F, Verweij J, Oster W, Vermorken JB.
    Ann Oncol; 1999 Jun 15; 10(6):693-700. PubMed ID: 10442192
    [Abstract] [Full Text] [Related]

  • 3. Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer.
    Ramnath N, LoRusso P, Simon M, Martino S.
    Am J Clin Oncol; 1997 Aug 15; 20(4):368-72. PubMed ID: 9256891
    [Abstract] [Full Text] [Related]

  • 4. Study of cisplatin-vinblastine plus amifostine in patients with locally advanced or metastatic non-small cell lung cancer.
    Thongprasert S, Chewaskulyong B.
    J Med Assoc Thai; 2004 Oct 15; 87(10):1162-7. PubMed ID: 15560691
    [Abstract] [Full Text] [Related]

  • 5. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
    Tannehill SP, Mehta MP, Larson M, Storer B, Pellet J, Kinsella TJ, Schiller JH.
    J Clin Oncol; 1997 Aug 15; 15(8):2850-7. PubMed ID: 9256128
    [Abstract] [Full Text] [Related]

  • 6. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
    Marina N, Chang KW, Malogolowkin M, London WB, Frazier AL, Womer RB, Rescorla F, Billmire DF, Davis MM, Perlman EJ, Giller R, Lauer SJ, Olson TA, Children's Oncology Group.
    Cancer; 2005 Aug 15; 104(4):841-7. PubMed ID: 15999362
    [Abstract] [Full Text] [Related]

  • 7. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival.
    Schiller JH, Storer B, Berlin J, Wittenkeller J, Larson M, Pharo L, Larson M, Berry W.
    J Clin Oncol; 1996 Jun 15; 14(6):1913-21. PubMed ID: 8656260
    [Abstract] [Full Text] [Related]

  • 8. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.
    Moore DH, Donnelly J, McGuire WP, Almadrones L, Cella DF, Herzog TJ, Waggoner SE, Gynecologic Oncology Group.
    J Clin Oncol; 2003 Nov 15; 21(22):4207-13. PubMed ID: 14615449
    [Abstract] [Full Text] [Related]

  • 9. Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686).
    Glover D, Ibrahim J, Kirkwood J, Glick J, Karp D, Stewart J, Ewell M, Borden E, Eastern Cooperative Oncology Group.
    Melanoma Res; 2003 Dec 15; 13(6):619-26. PubMed ID: 14646626
    [Abstract] [Full Text] [Related]

  • 10. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U, Wilke H, Seeber S.
    Semin Oncol; 1996 Oct 15; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC).
    Kusenda Z, Kerger J, Awada A, Geurs F, Van Vreckem A, Habboubi N, Piccart MJ.
    Support Care Cancer; 1997 Sep 15; 5(5):414-6. PubMed ID: 9322355
    [Abstract] [Full Text] [Related]

  • 13. The potential of amifostine: from cytoprotectant to therapeutic agent.
    Santini V, Giles FJ.
    Haematologica; 1999 Nov 15; 84(11):1035-42. PubMed ID: 10553165
    [Abstract] [Full Text] [Related]

  • 14. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
    Chang AY, Kim K, Boucher H, Bonomi P, Stewart JA, Karp DD, Blum RH.
    Cancer; 1998 Jan 15; 82(2):292-300. PubMed ID: 9445185
    [Abstract] [Full Text] [Related]

  • 15. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
    Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J.
    J Clin Oncol; 1996 Jul 15; 14(7):2101-12. PubMed ID: 8683243
    [Abstract] [Full Text] [Related]

  • 16. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
    Capizzi RL.
    Semin Oncol; 1999 Apr 15; 26(2 Suppl 7):72-81. PubMed ID: 10348264
    [Abstract] [Full Text] [Related]

  • 17. Amifostine for protection from antineoplastic drug toxicity.
    Foster-Nora JA, Siden R.
    Am J Health Syst Pharm; 1997 Apr 01; 54(7):787-800. PubMed ID: 9099346
    [Abstract] [Full Text] [Related]

  • 18. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
    Vaira M, Barone R, Aghemo B, Mioli PR, De Simone M.
    Minerva Med; 2001 Aug 01; 92(4):207-11. PubMed ID: 11535965
    [Abstract] [Full Text] [Related]

  • 19. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y, Droz JP, Chauvin F, Blay JY.
    Cancer; 1998 Jan 01; 82(1):134-40. PubMed ID: 9428489
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.